アブストラクト
| Title | GLP-1受容体作動薬の多面的作用 |
|---|---|
| Subtitle | 特集1 アウトカムを意識した SGLT2阻害薬・インクレチン関連薬の使い方 インクレチン関連薬の多面的作用 |
| Authors | 田矢直大, 片上直人 |
| Authors (kana) | |
| Organization | 大阪大学大学院医学系研究科内分泌・代謝内科学 |
| Journal | 月刊薬事 |
| Volume | 65 |
| Number | 1 |
| Page | 47-52 |
| Year/Month | 2023 / 1 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | 「Key Point」●GLP-1受容体作動薬は膵β細胞からのインスリン分泌促進を主作用とする2型糖尿病治療薬である. ●GLP-1受容体作動薬が心血管アウトカムおよび腎アウトカムを改善させることが臨床研究で示された. ●GLP-1受容体作動薬には膵β細胞への作用に加え, 抗動脈硬化作用, 抗肥満効果, 腎保護効果など多面的作用がある. ●GLP-1受容体作動薬はその多面的作用から, さまざまな病態, 合併症・併存疾患をもつ2型糖尿病症例で使用が検討される. ●特に, 心血管合併症, 腎合併症のある2型糖尿病症例ではGLP-1受容体作動薬の使用を考慮すべきである. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Muller TD, et al:Glucagon-like peptide 1(GLP-1). Mol Metab, 30:72-130, 2019
- 2) Pfeffer MA, et al;ELIXA Investigators:Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med, 373:2247-2257, 2015
- 3) Marso SP, et al;LEADER Steering Committee;LEADER Trial Investigators:Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 375:311-322, 2016
- 4) Marso SP, et al;SUSTAIN-6 Investigators:Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 375:1834-1844, 2016
- 5) Holman RR, et al;EXSCEL Study Group:Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 377:1228-1239, 2017
残りの17件を表示する
- 6) Hernandez AF, et al;Harmony Outcomes committees and investigators:Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes):a double-blind, randomised placebocontrolled trial. Lancet, 392:1519-1529, 2018
- 7) Gerstein HC, et al;REWIND Investigators:Dulaglutide and cardiovascular outcomes in type 2 diabetes(REWIND):a double-blind, randomised placebo-controlled trial. Lancet, 394:121-130, 2019
- 8) Husain M, et al;PIONEER 6 Investigators:Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 381:841-851, 2019
- 9) Gerstein HC, et al;AMPLITUDE-O Trial Investigators: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med, 385:896-907, 2021
- 10) Sattar N, et al:Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes:a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol, 9:653-662, 2021
- 11) Tuttle KR, et al:Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease(AWARD-7):a multicentre, openlabel, randomised trial. Lancet Diabetes Endocrinol, 6:605-617, 2018
- 12) Nauck MA, et al:GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab, 46:101102, 2021
- 13) Wang B, et al:Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide:a meta-analysis of clinical trials. Diabetes Obes Metab, 15 :737-749, 2013
- 14) Drucker DJ:GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab, 57:101351, 2022
- 15) Mosterd CM, et al:Nephroprotective effects of GLP-1 receptor agonists:where do we stand? J Nephrol, 33:965-975, 2020
- 16) Vitale M, et al:Renal protection with glucagon-like peptide-1 receptor agonists. Curr Opin Pharmacol, 54:91-101, 2020
- 17) Mantovani A, et al:Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis:An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites, 11:73, 2021
- 18) Ben-Shlomo S, et al:J Hepatol, 54:1214-1223, 2011
- 19) Hazlehurst JM, et al:Non-alcoholic fatty liver disease and diabetes. Metabolism, 65:1096-1108, 2016
- 20) American Diabetes Association Professional Practice Committee, et al:9. Pharmacologic Approaches to Glycemic Treatment:Standards of Medical Care in Diabetes-2022. Diabetes Care, 45(Suppl 1):S125-S143, 2022
- 21) 坊内良太郎, 他:2型糖尿病の薬物療法のアルゴリズム. 糖尿病, 65:419-434, 2022
- 22) Monami M, et al:Safety issues with glucagon-like peptide-1 receptor agonists(pancreatitis, pancreatic cancer and cholelithiasis):Data from randomized controlled trials. Diabetes Obes Metab, 19:1233-1241, 2017
